In the past ten years, China's "magic medicine" has finally come into the market, snapping up the global 10 billion market!

Wonderful content on December 2, Shuanglu pharmaceutical industry announced that it had received the new drug certificate and drug registration approval document of lenalidomide approved and issued by CFDA, which was more than ten years from the establishment of lenalidomide in Shuanglu pharmaceutical industry Ten years of sharpening a sword, Shuanglu pharmaceutical industry finally ushered in a good day for the approval of Nadu amine, all doubts disappeared Next, the domestic lenalidomide and the original research products compete for the domestic multiple myeloma market
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> lenalidomide, a drug developed by celgene to treat myelodysplastic syndrome, is the market leader of anti myeloma drugs Before the approval of Shuanglu, there was no lenalidomine independently developed in China, and all related drugs were imported Lenalidomine developed by Shuanglu pharmaceutical industry is the first one to be listed in China, so this drug is also regarded as a heavy product of Shuanglu pharmaceutical industry The reason why it has attracted much attention is that the price of lenalidomine is not cheap and it is likely to become a new global "drug king" The average price of rifeme is more than 50000 yuan For example, the price of 10mg dose is more than 46000 yuan, and that of 25mg dose is 60000 yuan This is the price of 21 pills The average price of each pill is 2200-2800 yuan Figure 1: global sales of new base Pharma in 2013-2016 data source: the global sales volume of lenalidomide in MNC's performance base in 2016 was as high as US $6.974 billion, and the sales volume in the first nine months of this year was US $5.999 billion With the continuous expansion of indications, the sales volume in 2022 is expected to be US $13.44 billion, which will become the highest sales volume of tumor drugs in the world Figure 2: Sales of rifformis in China's public medical institutions from 2013 to 2016 Data source: advanced database of minenet Then look at the domestic situation Rifformis was approved to enter the Chinese market in 2013 Rifformis is an urgent drug for clinical treatment of multiple myeloma in China, and it is also the best drug for treatment of multiple myeloma at present In this case, the sales volume of Rimage capsule increased rapidly In the chemical medicine pattern of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions), the sales volume of rifeme reached 44.25 million yuan in 2016, up 66.38% year on year In addition, ruifumei entered the national medical insurance catalog through national negotiation this year Although the price drop is close to 60%, the price of 10mg is still 866 yuan, and the price of 25mg is still 1102 yuan Therefore, the company's performance is expected to be strongly stimulated after lenalidomide, which is produced by Shuanglu pharmaceutical, is approved and listed exclusively At present, the imported lenadelamine has been approved to be owned by the original research company new base pharmaceutical, while the approved clinical products are currently several, such as Jiangsu Haosen, Zhengda Tianqing, Lianyungang Runzhong pharmaceutical, Qilu pharmaceutical, etc
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: RGB (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the sales contribution rate of compound coenzyme exceeds 70% Shuanglu pharmaceutical industry mainly focuses on the research, development, production and operation of genetic engineering and related drugs, closely around the change of disease spectrum The main products include compound coenzyme, arsenic trioxide, loratadine dispersible tablets, thymopentin, recombinant human granulocyte stimulating factor, recombinant human interleukin-2, recombinant human basic fibroblast growth factor, enoxaparin sodium, Xingling drop, etc
Among them, the compound coenzyme for injection (beconone / xinbeco) is the main product of Shuanglu pharmaceutical industry, which is used for acute and chronic hepatitis, primary thrombocytopenic purpura, leukopenia and thrombocytopenia caused by chemotherapy and radiotherapy; auxiliary treatment of coronary arteriosclerosis, chronic arteritis, myocardial infarction, oliguria and uremia caused by renal insufficiency, etc at present, the product has entered many provinces List of class B medical insurance The compound coenzyme for injection belongs to the exclusive product, ranking among the top 20 best-selling drugs in China Because the preparation method is complex and complex, it is very difficult to copy, so the future profits are still guaranteed Table 1: sales contribution rate of over 100 million varieties of Shuanglu pharmaceutical, a public medical institution in China in 2016 data source: advanced database of minenet According to the data of mienei.com, in 2016, the sales volume of five varieties of Shuanglu pharmaceutical industry exceeded 100 million, including compound coenzyme, thymopentin, recombinant human interleukin-2, loratadine and recombinant human granulocyte stimulating factor, of which the sales contribution rate of compound coenzyme exceeded 70%
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the performance is in reverse Figure 3: the performance of Shuanglu pharmaceutical industry in 2017 (unit: 10000 yuan) In the first three quarters of this year, Shuanglu pharmaceutical industry realized an operating revenue of 774 million yuan, an increase of 10.75% year on year; and realized a net profit of 391 million yuan, an increase of 9.41% year on year Among them, Q3's single quarter revenue was 308 million yuan, up 35.95% year-on-year, and its single quarter net profit was 158 million yuan, up 52.58% year-on-year From the data point of view, the company's performance began to show signs of improvement since the Q2 quarterly report in 2017, which was further confirmed in Q3 quarterly report in 2017 Shuanglu pharmaceutical expects the company to achieve a net profit of 452-520 million yuan in 2017, an increase of 0% - 15% year-on-year, mainly due to the gradual enrichment of listed products, market expansion, and increased sales revenue
At present, in addition to lenalidomide and ornidazole, the products to be marketed in Shuanglu pharmaceutical industry include ademetionine succinate for injection, which is suitable for intrahepatic cholestasis and intrahepatic cholestasis in pregnancy before and after cirrhosis, and glutathione enteric coated capsules for liver protection treatment of mild and moderate chronic hepatitis B the company has highly reported these four varieties It is expected that the above-mentioned products will play an important role in promoting the performance of Shuanglu pharmaceutical industry in the next few years.